Lundbeck Canada launches a new treatment for a rare form of acute leukemia: acute promyelocytic leukemia Trisenox® is now available in Canada MONTREAL, Nov. 13, 2013 /CNW/ - Health Canada has recently approved Trisenox® (arsenic trioxide) for relapsed or refractory acute promyelocytic leukemia (APL). This was made possible by a decision from Health Canada's Therapeutic Products Directorate to remove a prior regulatory prohibition on arsenic containing drug therapies for use in humans and by ...
Nov. 13, 2013 - PR Newswire via Yahoo! Finance